Cogent Biosciences, Inc.

NASDAQ•COGT

CEO: Mr. Andrew R. Robbins M.B.A.

セクター: Healthcare

業種: Biotechnology

上場日: 2018-03-29

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

連絡先情報

275 Wyman Street, 3rd Floor, Waltham, MA, 02451, United States

617-945-5576

www.cogentbio.com

時価総額

$6.01B

PER (TTM)

-7.6

19.7

配当利回り

52週高値

$43.73

52週安値

$3.72

52週レンジ

83%

順位47Top 61.9%

3.4

F-Score

改良版 Piotroski 分析

10年ファンダメンタル

弱い • 3.4 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2016-2025

財務ダッシュボード

Q4 2025 データ

売上高

$0.00+0.00%

直近4四半期の推移

EPS

-$0.69+0.00%

直近4四半期の推移

フリーCF

-$79.92M+0.00%

直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Bezuclastinib Clinical Progress Positive top-line results achieved for SM and GIST indications in 2025; NDA submission for NonAdvSM completed.

Financing Activities Strong Financing provided $878.2M in 2025, including $222.8M from Notes issuance, bolstering capital resources.

Cash Position Strong Cash, equivalents, and securities totaled $900.8M as of December 31, 2025, funding operations into 2028.

R&D Spending Increased Research and development expenses rose $37.1M to $269.78M in 2025, supporting clinical trial progression.

リスク要因

Continued Net Losses Incurred Net loss reached $328.94M in 2025, increasing $73.08M from 2024; operations remain unprofitable.

Pipeline Dependency Risk Business success highly dependent on bezuclastinib program success; pipeline expansion requires substantial funding.

Manufacturing Sole Source Risk API and drug product for bezuclastinib rely on single-source suppliers; loss significantly harms business operations.

Regulatory Approval Uncertainty Regulatory plans may face disagreement from FDA; approval for all indications is not guaranteed.

見通し

Commercial Launch Planned Expect US commercial launch for NonAdvSM in second half of 2026, pending successful FDA regulatory approval.

Pipeline Advancement Continues Plan to initiate Phase 1 study for ErbB2 inhibitor and submit IND for KRAS/JAK2 programs in 2026.

Future Capital Requirements Expect substantial future expenses; additional financing required to complete development and commercialization efforts.

GIST NDA Submission Target Expect to complete GIST NDA submission in April 2026, following RTOR acceptance in January 2026.

同業比較

売上高 (TTM)

SRPT

$2.20B

+15.6%

GLPG

$1.26B

+303.5%

RCUS

$247.00M

-4.3%

粗利益率 (最新四半期)

AGIO

96.9%

-4.3pp

LQDA

94.2%

+29.3pp

RCUS

90.9%

-7.7pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
IBRX	$9.25B	-25.3	64.3%	175.0%
COGT	$6.01B	-7.6	-100.2%	27.0%
DNLI	$3.18B	-7.0	-50.1%	3.7%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

N/M

売上高の変動が大きい

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年5月4日

EPS:-

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし